Y10S 424/809
Involving immunoglobulin or antibody fragment
Official title: involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Y10S424/809 (Involving immunoglobulin or antibody fragment) appears on 137 US grants and 65 published applications in this corpus.
Search patents in Y10S- Granted patents
- 137
- Published applications
- 65
- Assignees
- 90
- Inventors
- 235
- Latest grant
- 8 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 5 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 6 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 2 | 0 |
| 1998 | 14 | 0 |
| 1999 | 9 | 0 |
| 2000 | 5 | 0 |
| 2001 | 9 | 2 |
| 2002 | 3 | 6 |
| 2003 | 5 | 6 |
| 2004 | 4 | 3 |
| 2005 | 2 | 7 |
| 2006 | 5 | 1 |
| 2007 | 3 | 4 |
| 2008 | 4 | 1 |
| 2009 | 7 | 5 |
| 2010 | 1 | 6 |
| 2011 | 8 | 2 |
| 2012 | 4 | 4 |
| 2013 | 4 | 4 |
| 2014 | 4 | 2 |
| 2015 | 4 | 4 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 1 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Anti-PCSK9 antibodies8 Apr 2025US 12,269,897 B2Regeneron Pharmaceuticals, Inc.
- Anti-PCSK9 antibodies9 Mar 2021US 10,941,210 B2Regeneron Pharmaceuticals, Inc.
- Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs18 Feb 2020US RE47,860 E1Novartis AG
- Anti-PCSK9 antibodies17 Jul 2018US 10,023,654 B2Regeneron Pharmaceuticals, Inc.
- Therapeutic uses of anti-PCSK9 antibodies24 Jan 2017US 9,550,837 B2Regeneron Pharmaceuticals, Inc.
- Anti-pcsk9 antibodies15 May 2025US 2025/0154286 A1Regeneron Pharmaceuticals, Inc.
- Anti-pcsk9 antibodies26 Oct 2023US 2023/0340153 A1Regeneron Pharmaceuticals, Inc.
- Antibodies against clostridium difficile toxins and uses thereof2 Sep 2021US 2021/0269511 A1E. R. Squibb & Sons, Inc.
- Anti-pcsk9 antibodies19 Aug 2021US 2021/0253735 A1Regeneron Pharmaceuticals, Inc.
- Anti-pcsk9 antibodies9 May 2019US 2019/0135941 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- CTLA4 receptor and uses thereof174US 5,977,318 ABristol-Myers Squibb Company · 1999
- High affinity human antibodies to PCSK9143US 8,062,640 B2Regeneron Pharmaceuticals, Inc. · 2011
- CTLA4 receptor and uses thereof111US 5,885,796 ABristol-Myers Squibb Company · 1999
- Soluble CTLA4 molecules and uses thereof107US 5,851,795 ABristol-Myers Squibb Company · 1998